Key Takeaways
- First true oral GLP-1 pill — no injection, no food timing restrictions
- Small molecule drug with significantly better oral bioavailability than Rybelsus
- Phase 2: ~14.7% average weight loss at 36 weeks
- Phase 3 ATTAIN program is underway; results expected 2025–2026
- Potential FDA approval as early as late 2026 or 2027
- Cannot currently be purchased or prescribed in the US
What Is Orforglipron?
Orforglipron (LY3502970) is an investigational once-daily oral medication being developed by Eli Lilly for obesity and type 2 diabetes. Its defining feature: it is a non-peptide small molecule, which is what allows it to be taken as a pill without the strict food restrictions that make Rybelsus difficult to use in real life.
Why "True Oral" Matters
| Orforglipron | Rybelsus (oral sema) | Wegovy (injectable) | |
|---|---|---|---|
| Form | Daily pill, no restrictions | Daily pill, strict fasting | Weekly injection |
| Food restrictions | None | 30-min fast required | None |
| Avg weight loss | ~15% | ~5–8% | ~15% |
| Approved for obesity | No (Phase 3) | No (diabetes only) | Yes |
| Available now | No | Yes | Yes |
Phase 2 Results
Published in the New England Journal of Medicine (2023), the Phase 2 obesity trial showed:
- Average weight loss at 120mg dose: 14.7% of body weight at 36 weeks
- 28% of participants lost 15% or more of body weight
- In type 2 diabetes patients: HbA1c reduction up to 2.1 percentage points
- Side effect profile: nausea, diarrhea, constipation — consistent with GLP-1 class
Phase 3: The ATTAIN Program
Eli Lilly launched the ATTAIN Phase 3 program, covering adults with obesity, type 2 diabetes, cardiovascular outcomes, and PCOS. Key results are expected late 2025 to 2026.
| Milestone | Estimated Timing |
|---|---|
| ATTAIN Phase 3 results | Late 2025 – 2026 |
| NDA submission | 2026 (estimated) |
| FDA review | 12 months |
| Earliest approval | Late 2026 – 2027 |
For the broader pipeline picture, see the approval timeline or compare all pipeline drugs. Explore the full future GLP-1 hub.
Frequently Asked Questions
Is orforglipron available?
No. It is investigational and not FDA-approved. It cannot be purchased or prescribed in the US.
How does it differ from Rybelsus?
Rybelsus (oral semaglutide) requires strict food timing — 30 minutes fasting before taking it. Orforglipron has no food restrictions and has much better oral bioavailability because it is a small molecule, not a peptide.
When could orforglipron be approved?
Phase 3 ATTAIN results are expected in late 2025 to 2026. FDA approval could come as early as late 2026 or 2027, making it potentially the next GLP-1 drug approved.
How much weight does orforglipron produce?
Phase 2 showed ~14.7% average body weight loss at 36 weeks at the highest dose — comparable to injectable semaglutide in trials of similar length.
What can I do now?
Semaglutide (Wegovy) and tirzepatide (Zepbound) are available now through licensed telehealth providers in most states.
Waiting for a pill? Options exist today.
While orforglipron completes Phase 3, licensed telehealth providers offer FDA-approved GLP-1 medications in most states — some oral, many without insurance requirements.
Take Quiz — Free